Research Tracker›Biomarker Atlas›Long COVID›Gut microbiome alpha diversity

Gut microbiome alpha diversity in Long COVID

Gut microbiome alpha diversity, also described as Shannon index, is a microbiome marker reported as reduced in Long COVID (PASC, Post-Acute Sequelae of COVID-19) when patients are compared with healthy controls. Symptom domains tied to this marker in the source include GI symptoms, dysbiosis. This entry summarises Baalbaki et al. 2025. Group-level associations like this do not translate into an individual diagnostic cut-off.

↓ ReducedMicrobiome

Summary

Direction in Long COVID↓ Reduced — lower than in the comparison group
CategoryMicrobiome
Also described asShannon index
Compared againstHC (healthy controls)
Associated symptomsGI symptoms, dysbiosis
Test typeBlood test (serum / plasma / whole blood)
SourceBaalbaki et al. 2025 — doi:10.1111/all.16526
Condition atlasLong COVID Biomarker Atlas

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term Change in gut microbiota diversity and richness (1 registered trials use a matching outcome measure).

Clinical trials using Gut microbiome alpha diversity as an outcome

Related Microbiome markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is Gut microbiome alpha diversity high or low in Long COVID?

Reduced. Studies summarised in the OSMF atlas report lower Gut microbiome alpha diversity in Long COVID than in healthy controls. Source: Baalbaki et al. 2025.

What symptoms is Gut microbiome alpha diversity associated with in Long COVID?

The cited literature associates this marker with GI symptoms, dysbiosis. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Gut microbiome alpha diversity?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal Gut microbiome alpha diversity result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. Gut microbiome alpha diversity findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). Gut microbiome alpha diversity in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/gut-microbiome-alpha-diversity.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.